Riana Lo Bu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Riana Lo Bu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Frank Soldner
Aligning Science Across Parkinsonʼs ASAP Collaborative Research Network Albert Einstein College of Medicine 1301 Morris Park Ave. 10461 20815. Bronx Chevy Chase NY MD USA.
3 shared publications- Dirk Hockemeyer
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, USA
2 shared publications - Hanqin Li
Aligning Science Across Parkinsonʼs ASAP Collaborative Research Network University of California 94720 2081 Berkeley Berkeley Chevy Chase CA MD USA
2 shared publications - Khaja Mohieddin Syed
Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, USA
2 shared publications - Oriol Busquets
Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Rose F. Kennedy Center, Albert Einstein College of Medicine
2 shared publications - Allison Hh Martin
Cook County Medical Examiner’s Office
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 69 (1) , 166-170
Allergic Reaction to a Bovine-Derived Dural Graft without Eosinophilic Meningitis : A Case Report and Literature Review
Bovine-derived dural substitutes are commonly used in cranial and spinal duraplasty. Although they are generally well tolerated, allergic reactions have been reported—almost all presented with eosinophilic meningitis. A 7-year-old girl with Li-Fraumeni syndrome and diffuse pediatric glioma underwent a third salvage resection in which a bovine collagen dural onlay was placed. Ten days post operatively, she developed fever, lethargy, and a subcutaneous scalp fluid collection. Cultures and imaging were negative for infection; cerebrospinal fluid (CSF) revealed pleocytosis (elevated white blood cells and protein) without eosinophilia. High-dose dexamethasone produced transient clinical and radiographic improvement, but fever and fluid re accumulated whenever steroids were tapered. Given the steroid dependence and persistently negative infectious work-up, the graft was explanted. Pathology demonstrated a foreign-body giant cell reaction without eosinophils, and the patient’s symptoms resolved permanently after removal. This report documents the first pediatric case of bovinederived dural graft hypersensitivity without eosinophilic meningitis. Clinicians should consider graft-related allergy in children who develop recurrent fluid collections and fevers after duraplasty—even when CSF eosinophils are absent and cultures remain negative and should recognize that definitive treatment may require graft removal rather than prolonged steroid therapy.
- 1 January 2026
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 69 (1) , 166-170
Open AccessAllergic Reaction to a Bovine-Derived Dural Graft without Eosinophilic Meningitis : A Case Report and Literature Review
Bovine-derived dural substitutes are commonly used in cranial and spinal duraplasty. Although they are generally well tolerated, allergic reactions have been reported—almost all presented with eosinophilic meningitis. A 7-year-old girl with Li-Fraumeni syndrome and diffuse pediatric glioma underwent a third salvage resection in which a bovine collagen dural onlay was placed. Ten days post operatively, she developed fever, lethargy, and a subcutaneous scalp fluid collection. Cultures and imaging were negative for infection; cerebrospinal fluid (CSF) revealed pleocytosis (elevated white blood cells and protein) without eosinophilia. High-dose dexamethasone produced transient clinical and radiographic improvement, but fever and fluid re accumulated whenever steroids were tapered. Given the steroid dependence and persistently negative infectious work-up, the graft was explanted. Pathology demonstrated a foreign-body giant cell reaction without eosinophils, and the patient’s symptoms resolved permanently after removal. This report documents the first pediatric case of bovinederived dural graft hypersensitivity without eosinophilic meningitis. Clinicians should consider graft-related allergy in children who develop recurrent fluid collections and fevers after duraplasty—even when CSF eosinophils are absent and cultures remain negative and should recognize that definitive treatment may require graft removal rather than prolonged steroid therapy.
- Open Access
iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder caused by complex genetic and environmental factors. Genome-edited human pluripotent stem cells (hPSCs) offer a unique experimental platform to advance our understanding of PD etiology by enabling the generation of disease-relevant cell types carrying patient mutations along with isogenic control cells. To facilitate this approach, we generated a collection of 65 human stem cell lines genetically engineered to harbor high risk or causal variants in genes associated with PD ( SNCA A53T, SNCA A30P, PRKN Ex3del, PINK1 Q129X, DJ1/PARK7 Ex1-5del, LRRK2 G2019S, ATP13A2 FS, FBXO7 R498X/FS, DNAJC6 c.801 A>G/FS, SYNJ1 R258Q/FS, VPS13C A444P/FS, VPS13C W395C/FS, GBA1 IVS2+1/FS). All mutations were introduced into a fully characterized and sequenced female human embryonic stem cell (hESC) line (WIBR3; NIH approval number NIHhESC-10-0079) using different genome editing techniques. To ensure the genetic integrity of these cell lines, we implemented rigorous quality controls, including whole-genome sequencing of each line. Our analysis of the genetic variation in this cell line collection revealed that while genome editing, particularly using CRISPR/Cas9, can introduce rare off-target mutations, the predominant source of genetic variants arises from routine cell culture and are fixed in cell lines during clonal isolation. The observed genetic variation was minimal compared to that typically found in patient-derived iPSC experiments and predominantly affected non-coding regions of the genome. Importantly, our analysis outlines strategies for effectively managing genetic variation through stringent quality control measures and careful experimental design. This systematic approach ensures the high quality of our stem cell collection, highlights advantages of prime editing over conventional CRISPR/Cas9 methods and provides a roadmap for the generation of gene-edited hPSC collections at scale in an academic setting. Our iSCORE-PD collection represents an easily accessible and valuable platform to study PD, which can be used by investigators to understand the molecular pathophysiology of PD in a human cellular setting.
Open AccessiSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder caused by complex genetic and environmental factors. Genome-edited human pluripotent stem cells (hPSCs) offer a unique experimental platform to advance our understanding of PD etiology by enabling the generation of disease-relevant cell types carrying patient mutations along with isogenic control cells. To facilitate this approach, we generated a collection of 65 human stem cell lines genetically engineered to harbor high risk or causal variants in genes associated with PD ( SNCA A53T, SNCA A30P, PRKN Ex3del, PINK1 Q129X, DJ1/PARK7 Ex1-5del, LRRK2 G2019S, ATP13A2 FS, FBXO7 R498X/FS, DNAJC6 c.801 A>G/FS, SYNJ1 R258Q/FS, VPS13C A444P/FS, VPS13C W395C/FS, GBA1 IVS2+1/FS). All mutations were introduced into a fully characterized and sequenced female human embryonic stem cell (hESC) line (WIBR3; NIH approval number NIHhESC-10-0079) using different genome editing techniques. To ensure the genetic integrity of these cell lines, we implemented rigorous quality controls, including whole-genome sequencing of each line. Our analysis of the genetic variation in this cell line collection revealed that while genome editing, particularly using CRISPR/Cas9, can introduce rare off-target mutations, the predominant source of genetic variants arises from routine cell culture and are fixed in cell lines during clonal isolation. The observed genetic variation was minimal compared to that typically found in patient-derived iPSC experiments and predominantly affected non-coding regions of the genome. Importantly, our analysis outlines strategies for effectively managing genetic variation through stringent quality control measures and careful experimental design. This systematic approach ensures the high quality of our stem cell collection, highlights advantages of prime editing over conventional CRISPR/Cas9 methods and provides a roadmap for the generation of gene-edited hPSC collections at scale in an academic setting. Our iSCORE-PD collection represents an easily accessible and valuable platform to study PD, which can be used by investigators to understand the molecular pathophysiology of PD in a human cellular setting.
- Open Access
- 9 January 2024
- Published by Springer Nature
Immunocytochemistry v1
This protocol summarizes the steps to immunostain hPSCs or differentiated cultures. Protocol Overview A. Cell fixation B. Immunocytochemistry
- 9 January 2024
- Published by Springer Nature
Open AccessImmunocytochemistry v1
This protocol summarizes the steps to immunostain hPSCs or differentiated cultures. Protocol Overview A. Cell fixation B. Immunocytochemistry
- Open Access
- 9 January 2024
- Published by Springer Nature
Microglia validation by FACS-analysis v1
This protocol describes the procedure for microglial precursor and mature microglia validation by Fluorescence-Activated Cell Sorting (FACS) analysis. Please refer to (https://doi.org/10.17504/protocols.io.4r3l22zbjl1y/v1) for microglia differentiation protocol for cell generation and media composition. Protocol Overview A. Microglial precursor validation B. Mature microglia validation General Notes A list of reagents and relevant vendor information can be found in the table listed under the materials tab.
- 9 January 2024
- Published by Springer Nature
Open AccessMicroglia validation by FACS-analysis v1
This protocol describes the procedure for microglial precursor and mature microglia validation by Fluorescence-Activated Cell Sorting (FACS) analysis. Please refer to (https://doi.org/10.17504/protocols.io.4r3l22zbjl1y/v1) for microglia differentiation protocol for cell generation and media composition. Protocol Overview A. Microglial precursor validation B. Mature microglia validation General Notes A list of reagents and relevant vendor information can be found in the table listed under the materials tab.
- Open Access
- 8 January 2024
- Published by Springer Nature
Microglia differentiation v1
This protocol has been refined to differentiate microglia cells from hESC adapted to feeder free culture systems as described in the following protocol: Protocol Overview A. Flask Preparation B. Poly-D-Lysine (PDL) plate coating C. Media recipes D. Cell passage and differentiation E. Microglia precursor isolation and platting for maturation General Notes A list of reagents and relevant vendor information can be found in the table listed under the materials tab.
- 8 January 2024
- Published by Springer Nature
Open AccessMicroglia differentiation v1
This protocol has been refined to differentiate microglia cells from hESC adapted to feeder free culture systems as described in the following protocol: Protocol Overview A. Flask Preparation B. Poly-D-Lysine (PDL) plate coating C. Media recipes D. Cell passage and differentiation E. Microglia precursor isolation and platting for maturation General Notes A list of reagents and relevant vendor information can be found in the table listed under the materials tab.